| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
168,873 |
158,120 |
$5.63M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
9,240 |
9,211 |
$514K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
81,811 |
79,197 |
$511K |
| T1015 |
Clinic visit/encounter, all-inclusive |
18,236 |
17,075 |
$445K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
12,338 |
11,956 |
$300K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
22,321 |
11,095 |
$210K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
3,170 |
3,071 |
$121K |
| 87428 |
|
1,140 |
1,109 |
$61K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
1,811 |
1,767 |
$42K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
495 |
478 |
$37K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,291 |
1,288 |
$35K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
639 |
636 |
$31K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
621 |
608 |
$27K |
| 87081 |
|
7,325 |
7,177 |
$23K |
| 0001A |
|
491 |
491 |
$19K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
496 |
473 |
$19K |
| 0011A |
|
592 |
588 |
$19K |
| 0012A |
|
516 |
512 |
$19K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
44 |
44 |
$18K |
| 0002A |
|
431 |
430 |
$17K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
495 |
478 |
$12K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
191 |
190 |
$9K |
| 90686 |
|
554 |
540 |
$4K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
356 |
353 |
$4K |
| 0064A |
|
73 |
73 |
$3K |
| 0031A |
|
60 |
60 |
$2K |
| 99215 |
Prolong outpt/office vis |
23 |
23 |
$1K |
| 90670 |
|
125 |
123 |
$1K |
| 0004A |
|
16 |
16 |
$640.00 |
| 0071A |
|
16 |
16 |
$640.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
23 |
17 |
$575.18 |
| 0072A |
|
14 |
14 |
$560.00 |
| 90734 |
|
12 |
12 |
$372.18 |
| 90656 |
|
19 |
19 |
$289.71 |
| 94760 |
|
103 |
102 |
$265.40 |
| 99173 |
|
110 |
110 |
$140.75 |
| 81003 |
|
149 |
138 |
$94.51 |
| 90680 |
|
14 |
14 |
$90.50 |
| 91306 |
|
50 |
50 |
$49.00 |
| 91301 |
|
62 |
62 |
$45.00 |
| Q0244 |
Injection, casirivimab and imdevimab, 1200 mg |
43 |
43 |
$40.00 |
| 91300 |
|
181 |
174 |
$7.00 |
| 3079F |
|
845 |
813 |
$0.00 |
| 3074F |
|
4,984 |
4,778 |
$0.00 |
| 90677 |
|
15 |
15 |
$0.00 |
| 3075F |
|
88 |
81 |
$0.00 |
| 91307 |
|
24 |
20 |
$0.00 |
| 90697 |
|
14 |
14 |
$0.00 |
| 3078F |
|
4,232 |
4,056 |
$0.00 |
| 90633 |
|
12 |
12 |
$0.00 |
| 3077F |
|
12 |
12 |
$0.00 |
| 0502F |
|
60 |
41 |
$0.00 |